Overlapping Clinical Presentation of Long COVID and Postacute COVID-19 Vaccination Syndrome: Phenotypes, Severity, and Biomarkers.
Purpura, Lawrence, Heisler, Thomas, Palmer, Steven et al. · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026 · DOI
Quick Summary
This study compared three groups of people dealing with long-term effects from COVID-19: those with long COVID and ME/CFS, those with long COVID without ME/CFS, and those with symptoms after COVID-19 vaccination. While all three groups shared common symptoms like fatigue, the ME/CFS group experienced more widespread symptoms across their body. Interestingly, people in the vaccination-related group had higher rates of unusual symptoms like nerve pain and rashes, and their blood tests showed different patterns of autoimmune markers—substances that suggest the immune system may be attacking the body's own tissues.
Why It Matters
This study is important because it provides clinical evidence that ME/CFS and post-vaccination syndromes may involve similar autoimmune mechanisms, suggesting researchers should investigate shared underlying pathways. The identification of distinct biomarker patterns could help clinicians better characterize these conditions and potentially develop more targeted treatments. Understanding these differences and similarities may improve diagnostic accuracy and lead to more appropriate management strategies for ME/CFS patients.
Observed Findings
Fatigue was nearly universal across all groups, with 100% prevalence in the MECFS group, 92.86% in PACVS, and 78.05% in the LC group.
The MECFS group reported the highest overall symptom burden across multiple organ systems compared to other groups.
The PACVS group had significantly higher rates of specific atypical symptoms: peripheral neuropathy (17.9%), tinnitus (7.1%), and rash (10.7%) compared to other groups (P<0.01).
PACVS patients had higher anti-U1-RNP autoantibody positivity (21.4%) compared to LC patients (2.3%, P=0.04).
Inferred Conclusions
PASC and PACVS share symptom overlap but are distinguishable by symptom pattern, with PACVS presenting with more atypical features.
Autoimmune involvement appears central to both PASC and PACVS, but autoantibody signatures differ between groups, suggesting distinct immunologic mechanisms.
Elevated anticardiolipin and anti-U1-RNP antibodies in PACVS warrant investigation as potential biomarkers and therapeutic targets in vaccination-related post-acute syndromes.
Remaining Questions
Do the elevated autoantibodies in PACVS represent a distinct pathophysiologic mechanism compared to PASC, or are they markers of a similar underlying process?
What This Study Does Not Prove
This study does not prove that vaccination causes post-acute syndrome—it only describes symptom and biomarker patterns in patients who reported symptoms after vaccination. The cross-sectional design means researchers observed groups at one point in time, so cause-and-effect relationships cannot be established. Additionally, the small PACVS sample size (n=28) limits the generalizability of findings specific to that group, and the study cannot explain why some people develop these conditions while others recover normally.
Why does PACVS present with more peripheral neuropathy and tinnitus while PASC+MECFS shows broader multi-system involvement—are these different phenotypes of the same disease?
Could these biomarker patterns guide targeted immunologic therapies, and would treatments differ between PASC and PACVS populations?
How do these biomarker patterns change over time, and do they predict treatment response or recovery?